ProSciento’s NASH PASS proprietary diagnostic patient phenotyping and access program is highly differentiated from what multi-therapeutic CROs can provide. The NASH PASS, IRB-approved study protocol significantly accelerates site selection and patient enrollment for NAFLD/NASH clinical trials. The NASH PASS patient database is also utilized in study design to tailor study enrollment projections, feasibility analysis, and optimization of I/E criteria, resulting in significantly reduced screen fails, avoiding delays in enrollment, and providing reliable project study timelines.
